Director Marc Gruninger filed a Form 4 with the SEC on October 29, 2026, disclosing two open-market purchases of Ordinary Shares in Veraxa Biotech AG (NASDAQ:VRXA) made on October 27 and October 28, 2026.

Key Highlights

  • First purchase: Marc Gruninger acquired 867 Ordinary Shares on October 27, 2026, at a price of $0.98 per share.
  • Second purchase: Gruninger acquired an additional 9,133 Ordinary Shares on October 28, 2026, at a price of $1.00 per share.
  • Combined total: Following both transactions, Gruninger directly beneficially owns 10,000 Ordinary Shares, according to the filing.
  • Transaction code: Both transactions are coded "P" (open-market purchase) in the filing.
  • Role: The filing identifies Gruninger as a Director of Veraxa Biotech AG.
  • Ownership form: Both reported positions are held directly.

Marc Gruninger's Two-Day Purchase of Veraxa Biotech Ordinary Shares

According to the Form 4 filed October 29, 2026, Marc Gruninger, a director of Veraxa Biotech AG (NASDAQ:VRXA), reported two separate purchases of the company's Ordinary Shares executed on consecutive trading days. The first transaction, dated October 27, 2026, involved the acquisition of 867 shares at $0.98 per share. The second transaction, dated October 28, 2026, involved the acquisition of 9,133 shares at $1.00 per share. Both transactions are classified with transaction code "P," indicating open-market purchases.

Following these two reported transactions, the filing states that Gruninger directly beneficially owns 10,000 Ordinary Shares in total. The filing does not indicate that either transaction was made pursuant to a Rule 10b5-1 trading plan, as the corresponding checkbox on the form is not marked. No derivative securities transactions were reported in Table II of the filing.

Gruninger's address is listed in Zurich, Switzerland. The issuer is identified in the filing as "Veraxa Biotech AG - Post de-SPAC" with the ticker symbol VRXA. The filing was signed by Marc Gruninger on October 29, 2026.

What Was Disclosed

Director Marc Gruninger disclosed two open-market purchases of Veraxa Biotech AG Ordinary Shares totaling 10,000 shares, acquired at prices of $0.98 and $1.00 per share on October 27 and October 28, 2026, respectively, resulting in direct beneficial ownership of 10,000 shares.